Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Inspecs GroupLSE:SPEC 50 3-1 Month Momentum % is 16.17% as of Jul. 28, 2026. GuruFocus rates LSE:SPEC with a GF Score™ of 50/100 and a GF Value™ of £0.59 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 846 Medical Devices & Instruments companies, Inspecs Group ranks better than 88.77% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-28), Inspecs Group's 3-1 Month Momentum % is 16.17%.
The industry rank for Inspecs Group's 3-1 Month Momentum % or its related term are showing as below:
LSE:SPEC's 3-1 Month Momentum % is ranked better than 88.77% of 846
companies
in the Medical Devices & Instruments industry
Industry Median: -9.14
vs LSE:SPEC: 16.17
Inspecs Group (LSE:SPEC) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Inspecs Group 3-1 Month Momentum % Related Terms
LSE:SPEC vs ISRG, BDX, MDLN: 3-1 Month Momentum % Comparison
For the Medical Instruments & Supplies subindustry, Inspecs Group's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inspecs Group 3-1 Month Momentum % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Inspecs Group's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Inspecs Group's 3-1 Month Momentum % falls into.
Inspecs Group (LSE:SPEC) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inspecs Group (LSE:SPEC) has a 3-1 Month Momentum % of 16.17% as of Jul. 28, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Inspecs Group and its competitors. According to the industry distribution chart, Inspecs Group ranks #95 out of 846 companies in the Medical Devices & Instruments industry, placing it in the top 11.2%.
Is Inspecs Group's 3-1 Month Momentum % too high?
Inspecs Group's current 3-1 Month Momentum % is 16.17%. Based on the distribution chart, Inspecs Group ranks #95 out of 846 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Inspecs Group has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Inspecs Group's 3-1 Month Momentum % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Inspecs Group ranks #95 out of 846 companies for 3-1 Month Momentum %. This places Inspecs Group in the top 11% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Medical Devices & Instruments company?
A good 3-1 Month Momentum % depends on the Medical Devices & Instruments industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Inspecs Group and its competitors. Inspecs Group's current 3-1 Month Momentum % is 16.17%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inspecs Group stock overvalued right now?
Based on GuruFocus' analysis, Inspecs Group (LSE:SPEC) is currently considered Significantly Overvalued. The stock's GF Value™ is £0.59, compared to a current price of £0.96 — trading 62.7% above its estimated fair value. The current 3-1 Month Momentum % is 16.17%. Inspecs Group's overall GF Score™ is 50/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Inspecs Group (LSE:SPEC), the current 3-1 Month Momentum % is 16.17% as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Inspecs Group (LSE:SPEC) Overvalued in 2026?
Based on GuruFocus' analysis, Inspecs Group stock appears to be overvalued.
The current stock price of £0.96 is trading 62.7% above its estimated GF Value™ of £0.59.
GuruFocus considers Inspecs Group to be Significantly Overvalued.
Key valuation signals for LSE:SPEC:
3-1 Month Momentum %: 16.17%
GF Value™: £0.59 vs. price of £0.96 (62.7% above fair value)
No single metric tells the full story. See the LSE:SPEC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Inspecs Group PLC is a designer and manufacturer of eyewear frames and accessories. The customers of the company include optical and Non-optical retailers, distributors, and independent opticians. The company operations are spread across the United Kingdom, Europe (excluding the UK), South America, North America, Asia, Africa, and Australia. Its eyewear brands include Superdry, Titanflex, O'Neill, Brendel, Humphreys, Marc O'Polo, and among others. The reporting segments of the company are Frames and Optics product distribution which derives maximum revenue, and Manufacturing includes OEM and manufacturing distribution segment.
50GF Score
Get the complete analysis for LSE:SPEC
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:SPEC has been successfully added to your 
